Decreased IL-7 signaling in T cells from patients with PTLD after allogeneic HSCT

Journal of Immunotherapy

Volumn 34, Issue 4, 2011, Pages 390-396

  Omar, Hamdy ^a   Ahmed, Raija ^b   Rane, Lalit ^a   Björklund, Andreas ^a,c   Gustafsson Jernberg, Åsa ^c   Ljungman, Per ^a,c   Maeurer, Markus J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CD4+ T cells; EBV; HSCT; immune suppression; interleukin 7; interleukin 7 receptor; PTLD; T cells; tetramer

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 2; STAT5 PROTEIN; TETRAMER;

ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

CD8-POSITIVE T-LYMPHOCYTES; EPITOPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-7; LYMPHOPROLIFERATIVE DISORDERS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 79955591917     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318215e31b     Document Type: Article

References (30)

1. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208-2216. (Pubitemid 29467666)
2. Cohen J, Gandhi M, Naik P, et al. Increased incidence of EBVrelated disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol. 2005;129:229-239. (Pubitemid 40562444)
3. Brunstein CG, Weisdorf DJ, DeFor T, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood. 2006;108:2874-2880.
4. Sundin M, Le Blanc K, Ringden O, et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica. 2006;91:1059-1067. (Pubitemid 44204772)
5. Abraham N, Ma MC, Snow JW, et al. Haploinsufficiency identifies STAT5 as a modifier of IL-7-induced lymphomas. Oncogene. 2005;24:5252-5257. (Pubitemid 41192442)
6. Erlandsson L, Licence S, Gaspal F, et al. Both the pre-BCR and the IL-7Ralpha are essential for expansion at the pre-BII cell stage in vivo. Eur J Immunol. 2005;35:1969-1976. (Pubitemid 40862345)
7. Mackall CL, Fry TJ, Bare C, et al. IL-7 increases both thymicdependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood. 2001;97:1491-1497. (Pubitemid 32183777)
8. Liu X, Leung S, Wang C, et al. Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nat Med. 2010;16:191-197.
9. Hinrichs CS, Kaiser A, Paulos CM, et al. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood. 2009;114:596-599.
10. Omar H, Hagglund H, Gustafsson-Jernberg A, et al. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Transpl Infect Dis. 2009;11: 393-399.
11. Vudattu NK, Kuhlmann-Berenzon S, Khademi M, et al. Increased numbers of IL-7 receptor molecules on CD4+CD25- CD107a+ T-cells in patients with autoimmune diseases affecting the central nervous system. PLoS ONE. 2009;4:e6534.
12. Magalhaes I, Vudattu NK, Jager E, et al. Tumor antigenspecific T-cells are Present in the CD8alphaalpha+ T-cell effector-memory pool. J Immunother. 2008;31:840-848.
13. Vudattu NK, Magalhaes I, Hoehn H, et al. Expression analysis and functional activity of interleukin-7 splice variants. Genes Immun. 2009;10:132-140.
14. Rose T, Lambotte O, Pallier C, et al. Identification and biochemical characterization of human plasma soluble IL-7R: lower concentrations in HIV-1-infected patients. J Immunol. 2009;182:7389-7397.
15. Guppy AE, Rawlings E, Madrigal JA, et al. A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon- gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease. Transplantation. 2007;84:1534-1539. (Pubitemid 350294730)
16. Hadrup SR, Braendstrup O, Jacobsen GK, et al. Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells. Int J Cancer. 2006;119:831-838. (Pubitemid 44051446)
17. Catalina MD, Sullivan JL, Brody RM, et al. Phenotypic and functional heterogeneity of EBV epitope-specific CD8+ T cells. J Immunol. 2002;168:4184-4191. (Pubitemid 34298427)
18. Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood. 2002;99:3892-3904. (Pubitemid 35332024)
19. Vudattu NK, Magalhaes I, Schmidt M, et al. Reduced numbers of IL-7 receptor (CD127) expressing immune cells and IL-7-signaling defects in peripheral blood from patients with breast cancer. Int J Cancer. 2007;121:1512-1519. (Pubitemid 47328710)
20. Giron-Michel J, Menard F, Negrini S, et al. EBV-associated mononucleosis does not induce long-term global deficit in T-cell responsiveness to IL-15. Blood. 2009;113:4541-4547.
21. Nakayama J, Yamamoto M, Hayashi K, et al. BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3. Blood. 2009;113:1483-1492.
22. Cattaruzza L, Gloghini A, Olivo K, et al. Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma. Int J Cancer. 2009;125:1092-1101.
23. Benjamin D, Sharma V, Knobloch TJ, et al. B cell IL-7. Human B cell lines constitutively secrete IL-7 and express IL-7 receptors. J Immunol. 1994;152:4749-4757.
24. Sasson SC, Smith S, Seddiki N, et al. IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers. Cytokine. 2010; 50:58-68.
25. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682-687. (Pubitemid 43237609)
26. Whiteside TL. Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer?. Cancer Immunol Immunother. 2004;53:865-878. (Pubitemid 39312654)
27. Xie Y, Bai O, Yuan J, et al. Tumor apoptotic bodies inhibit CTL responses and antitumor immunity via membrane-bound transforming growth factor-beta1 inducing CD8+ T-cell anergy and CD4+ Tr1 cell responses. Cancer Res. 2009;69: 7756-7766.
28. Li J, Sze DM, Brown RD, et al. Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy. Blood. 2010;115: 3580-3588.
29. Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol. 2010;22:223-230.
30. Mangsbo SM, Sandin LC, Anger K, et al. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother. 2010;33:225-235.